HC Wainwright Issues Negative Estimate for EBS Earnings

Emergent BioSolutions Inc. (NYSE:EBS) – Equities research analysts at HC Wainwright cut their Q1 2026 earnings estimates for shares of Emergent BioSolutions in a research report issued to clients and investors on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of $0.86 for the quarter, down from their prior forecast of $0.87. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Emergent BioSolutions’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions’ Q3 2026 earnings at $1.10 EPS.

Separately, StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

Emergent BioSolutions Trading Up 21.2%

Shares of EBS opened at $6.66 on Friday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. Emergent BioSolutions has a 1 year low of $4.02 and a 1 year high of $15.10. The company has a 50 day simple moving average of $5.16 and a two-hundred day simple moving average of $7.80. The firm has a market cap of $361.22 million, a P/E ratio of -1.62 and a beta of 2.09.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.22. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The business had revenue of $222.20 million during the quarter, compared to analyst estimates of $218.50 million.

Emergent BioSolutions announced that its Board of Directors has initiated a share repurchase program on Monday, March 31st that authorizes the company to repurchase $50.00 million in shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase up to 19% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Activity at Emergent BioSolutions

In related news, Director Neal Franklin Fowler sold 35,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the sale, the director now directly owns 101,100 shares in the company, valued at $589,413. This trade represents a 25.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is currently owned by insiders.

Institutional Trading of Emergent BioSolutions

A number of institutional investors have recently bought and sold shares of the stock. Covestor Ltd lifted its position in Emergent BioSolutions by 5,458.5% in the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 2,893 shares during the last quarter. Northern Trust Corp lifted its position in Emergent BioSolutions by 2.6% in the fourth quarter. Northern Trust Corp now owns 145,889 shares of the biopharmaceutical company’s stock worth $1,395,000 after buying an additional 3,692 shares during the last quarter. EP Wealth Advisors LLC lifted its position in Emergent BioSolutions by 33.1% in the first quarter. EP Wealth Advisors LLC now owns 15,249 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,790 shares during the last quarter. LPL Financial LLC lifted its position in Emergent BioSolutions by 34.5% in the fourth quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 3,875 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Emergent BioSolutions by 40.4% in the first quarter. Bank of New York Mellon Corp now owns 17,003 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 4,894 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.